Lukyanov Sergei A, Titov Sergei E, Dzodzaeva Aria V, Vanushko Vladimir E, Beltsevich Dmitry G, Veryaskina Yuliya A, Kupriyanov Semyon V, Bondarenko Ekaterina V, Troshina Ekaterina A, Urusova Liliya S, Sergiyko Sergei V
Department of General Surgery, South Ural State Medical University, 454141 Chelyabinsk, Russia.
Department of the Structure and Function of Chromosomes, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Int J Mol Sci. 2025 Jul 3;26(13):6418. doi: 10.3390/ijms26136418.
The strategy of active surveillance for papillary thyroid microcarcinoma (PTMC) is becoming increasingly popular within the global medical community. A key criterion for selecting this strategy is the absence of any signs of lymphogenic or distant metastases. The present study assessed the diagnostic accuracy of molecular genetic markers for predicting the metastatic potential of patients with PTMC. We evaluated the expression levels of 33 molecular genetic markers in cytology samples from 92 patients with PTMC and confirmed histological diagnosis. Among these patients, 32 had metastases to regional cervical lymph nodes. Our findings revealed the upregulated expression of the , , and genes, as well as microRNA-146b, in patients with metastatic PTMC. Conversely, we found the downregulated expression of miRNA-7 and -148b in metastatic tumors. In metastatic tumors, significant reductions were observed in activity (11-fold), gene expression (8-fold), expression (4-fold), and expression (2.6-fold). All the markers exhibited high sensitivity (84.5-90.6%) in detecting metastatic PTMC, although the specificity proved to be low. The use of molecular markers to predict lymphogenic metastatic spread in patients with PTMC could enhance existing risk grading systems. Such assessments can already be applicable at the preoperative stage.
甲状腺微小乳头状癌(PTMC)的主动监测策略在全球医学界越来越受欢迎。选择该策略的一个关键标准是不存在任何淋巴源性或远处转移的迹象。本研究评估了分子遗传标记物预测PTMC患者转移潜能的诊断准确性。我们评估了92例PTMC患者细胞学样本中33种分子遗传标记物的表达水平,并确认了组织学诊断。在这些患者中,32例有颈部区域淋巴结转移。我们的研究结果显示,转移性PTMC患者中, 、 和 基因以及微小RNA-146b的表达上调。相反,我们发现转移性肿瘤中miRNA-7和-148b的表达下调。在转移性肿瘤中,观察到 活性(11倍)、 基因表达(8倍)、 表达(4倍)和 表达(2.6倍)显著降低。所有标记物在检测转移性PTMC时均表现出高敏感性(84.5 - 90.6%),尽管特异性较低。使用分子标记物预测PTMC患者的淋巴源性转移扩散可以完善现有的风险分级系统。此类评估在术前阶段就已适用。